Vinita Kailasanath is the Administrative Partner for Arnold & Porter's San Francisco and Silicon Valley offices. Ms. Kailasanath works with leading and emerging companies in connection with cutting-edge intellectual property issues and the discovery, development, commercialization and protection of new products and technologies. Her practice focuses on technology, intellectual property and data-driven transactions, including complex collaborations; licensing deals; strategic investments; data rights arrangements; development, research and commercial manufacturing, supply and distribution agreements; sponsored research agreements; mergers and acquisitions; and joint ventures. Ms. Kailasanath has particularly extensive experience in life sciences, medical device and digital health transactions, including those with an artificial intelligence/machine learning component.
Ms. Kailasanath also regularly advises on Software as-a- Service ("SaaS"), Infrastructure-as-a-Service ("IaaS" and Platform-as-a-Service ("PaaS") arrangements as well as other cloud-related considerations, especially in FinTech, EdTech and AdTech. She also counsels clients on confidentiality, trade secret, digital economy, sweepstakes/contest, and social media issues. Ms. Kailasanath also works with tax-exempt organizations in connection with technology and intellectual property issues and advises on the legal aspects of museums and art.
Ms. Kailasanath also often works on issues at the intersection of intellectual property and FDA regulation. She counsels clients regarding clinical trial agreements and related documents, citizen petitions to FDA, Form FDA 3542a submissions, Bayh-Dole related issues (including US manufacturing waiver requests), Orange Book listings, and BPCIA-related matters.
Ms. Kailasanath served as Editor-in-Chief of the Stanford Technology Law Review. She has also worked in the legal department of a leading alternative energy company specializing in the production of algal oils and bioproducts.
Prior to attending law school, Ms. Kailasanath conducted graduate-level neuroendocrinology research and co-authored several publications. She also worked as a life sciences marketing and sales management consultant.
- Enzyvant in the sale to Aceragen of an investigational enzyme replacement therapy to treat Farber Disease, a group of inherited metabolic disorders for which no disease-specific therapy exists, for an upfront payment and development and sales-based milestones up to $226 million, as well as tiered royalties on net sales.
- Astra Zeneca in agreements for the funding and global distribution of the University of Oxford's potential COVID-19 vaccine, as well as in the establishment of its global manufacturing and supply chain for the vaccine, including an agreement with the Serum Institute of India (SII).
- Global pharmaceutical company on its worldwide exclusive licensing agreement with a biotechnology company for an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases. The transaction reflected a deal value of $1.6 billion plus double-digit royalties on certain sales.
- Global manufacturer of imaging technologies on a license, development and collaboration agreement involving an imaging agent with cardiovascular applications. The transaction reflected a deal value of $65 million, plus double-digit royalties on certain sales.
- Biotechnology company in a collaboration, option and license agreement involving a platform for the non-viral delivery of expression technologies to affect expression of certain targets.
- Biotechnology company developing therapies based on gene delivery technology in an evaluation, feasibility and option agreement.
- Global pharmaceutical company in its divestment of a subsidiary including two key Attention Deficit Hyperactivity Disorder (ADHD) treatments and associated transition services agreements.
- Fortune 200 healthcare company in critical supply agreement with a sole-source supplier in connection with the settlement of nine-figure litigation.
- Multiple global biopharmaceutical and life sciences companies with complex clinical and commercial supply agreements.
- Medical device company in connection with the drafting and negotiation of numerous consulting, supply and development agreements with universities, development and supply partners around the world.
- Global life sciences company with the drafting and negotiation of a coronavirus and pandemic flu vaccine adjuvant trade secret license.
- Multiple pharmaceutical and specialty pharmaceutical companies with global clinical trial agreements, letters of indemnification and informed consent forms, and related issues including ePRO.
Technology Transactions (2021)
Healthcare: Life Sciences (2021)
- JD, Stanford Law School, 2010
- MS, Biological Sciences, Stanford University, 2004
- BA, Human Biology, Stanford University, 2004, with honors and distinction, Phi Beta Kappa
- District of Columbia
- US Court of Appeals for the Federal Circuit
- United States Court of Appeals, Federal Circuit, The Honorable Arthur J. Gajarsa
- Member, Licensing Executives Society
- Member, Food and Drug Law Institute California Planning Committee
- Member, ChIPs NextGen Summit Planning Committee
- Advisor, UCSF Health Hub
- Governor, Stanford Associates Board of Governors
- Co-Chair, Stanford Law School Alumni Association - Bay Area Chapter